Select a medication above to begin.
Nulojix
belatacept
Black Box Warnings .
Appropriate Use
admin. only by physicians experienced in immunosuppress. tx and mgmt of kidney transplant pts in adequate medical facility; physician responsible for maintenance tx should have all info needed for pt follow-up
Post-Transplant Lymphoproliferative Disorder
incr. risk post-transplant lymphoproliferative disorder w/ predominant CNS involvement, esp. in pts w/o immunity to Epstein-Barr virus (EBV); use in EBV seropositive pts only; do not use in EBV seronegative or unknown EBV serostatus pts
Immunosuppression
incr. susceptibility to infection and possible development of malignancies may result from immunosuppression
Liver Transplantation
use not recommended in liver transplant pts due to incr. risk of graft loss and death
Adult Dosing .
Dosage forms: INJ
Restricted Distribution in US
- [1-855-511-6180 or www.nulojixhcp.bmscustomerconnect.com for more info]
kidney transplant rejection prophylaxis
- [initial phase]
- Dose: 10 mg/kg/dose IV x1 on Days 1, 5, then end of wk 2, 4, 8, 12; Start: Day 1 prior to implantation; Info: for EBV seropositive pts; part of multi-drug regimen; round dose to nearest 12.5 mg increment
- [maintenance phase]
- Dose: 5 mg/kg/dose IV q4wk; Start: end of wk 16 post-transplant; Info: for EBV seropositive pts; part of multi-drug regimen; round dose to nearest 12.5 mg increment
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.